First Horizon Advisors’s Royalty Pharma RPRX Stock Holding History

First Horizon Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.16K	Buy	60 +48	+400%	+$1.59K	﹤0.01%	2019
2025 Q1	$374	Hold	12	–	–	﹤0.01%	2245
2024 Q4	$306	Sell	12 -20	-63%	-$530	﹤0.01%	2233
2024 Q3	$905	Hold	32	–	–	﹤0.01%	2153
2024 Q2	$844	Hold	32	–	–	﹤0.01%	2143
2024 Q1	$972	Hold	32	–	–	﹤0.01%	2163
2023 Q4	$899	Sell	32 -140	-81%	-$3.85K	﹤0.01%	2238
2023 Q3	$4.67K	Hold	172	–	–	﹤0.01%	1770
2023 Q2	$5.29K	Hold	172	–	–	﹤0.01%	1775
2023 Q1	$6.2K	Hold	172	–	–	﹤0.01%	1745
2022 Q4	$6.8K	Hold	172	–	–	﹤0.01%	1699
2022 Q3	$7K	Hold	172	–	–	﹤0.01%	1658
2022 Q2	$7K	Buy	172 +50	+41%	+$2.05K	﹤0.01%	1723
2022 Q1	$5K	Buy	+122	New	+$4.79K	﹤0.01%	1304

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

First Horizon Advisors's RPRX Position: Q2 2025 in Review

First Horizon Advisors increased its Royalty Pharma (RPRX) stake by 400% in Q2 2025, buying an estimated $1.59K and bringing the position to 60 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

First Horizon Advisors first reported a position in RPRX in Q1 2022 and has held it in 14 quarters since. The position peaked at $7K in Q3 2022. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

First Horizon Advisors held 60 shares of Royalty Pharma worth $2.16K as of Q2 2025.
First Horizon Advisors bought 48 Royalty Pharma shares in Q2 2025, an estimated $1.59K.
Royalty Pharma made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #2019 holding.
First Horizon Advisors first reported a position in Royalty Pharma in Q1 2022 and has held it in 14 quarters since.
First Horizon Advisors's Royalty Pharma position peaked at $7K in Q3 2022.
455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.